Low-cost PON platform for rapid micronutrient deficiency detection
Nexogen's NexiDx™ offers a low-cost PON platform for rapid detection of micronutrient deficiencies. Using advanced microfluidics and magnetic bead-based sample prep, it delivers accurate results in 20-25 minutes, suitable for various clinical settings.
Overview
Nexogen's NexiDx™ is an innovative Point-of-Need (PON) platform designed to rapidly identify micronutrient deficiencies through DNA/RNA assays. This cost-effective solution provides multiple assays within 20-25 minutes on a single disposable cartridge, capable of detecting up to 200 RNA/DNA targets with high accuracy. Suitable for urgent care clinics and pharmacies, NexiDx™ offers a significant reduction in cost, being 15 times cheaper than existing platforms, while maintaining laboratory-level accuracy with 95% sensitivity and 98% specificity.
Technical specifications
NexiDx™ incorporates several advanced technologies:
- Magnetic bead-based nucleic acid preparation: Achieves sample prep in 3-4 minutes on the same cartridge.
- Isothermal rolling circle amplification: Facilitates DNA target amplification with high accuracy.
- Universal microfluidics platform: No mechanical moving parts, adaptable to LAMP, enhancing reliability and reducing maintenance.
- Dual instrument versions: A lab version and a hand-held NexiHome™ device for at-home use, ensuring flexibility.
- Validated assays: Successfully tested on various samples, including saliva and blood, for different DNA/RNA targets.
Technology readiness level
This platform is currently at Technology Readiness Level 5, indicating it has been validated in a relevant environment. Further validation is planned, including the development of assay protocols for micronutrient deficiency SNPs and comparison with rtPCR standards.
About Nexogen, Inc.
Nexogen, Inc. is a San Diego-based biotechnology company founded in 2009 that specializes in developing rapid DNA and RNA diagnostic technologies for point-of-need applications. The company creates integrated diagnostic instruments and platforms that incorporate microfluidics, proprietary extraction methods, and accelerated biomolecular reactions using electric and magnetic fields. Key products include the NEXI-Dx, a microfluidic-based isothermal amplification platform; the CAS-100, an automated sample-to-answer system utilizing carbon array technology; and the NEXI-SP, a portable DNA extraction device. These tools are designed to streamline sample processing, amplification, and detection, typically delivering results in minutes rather than hours.
These solutions are intended to improve diagnostic accessibility in human and veterinary clinical settings, such as emergency rooms, urgent care clinics, and small hospitals. By providing rapid, low-complexity, and affordable molecular diagnostics, Nexogen aims to enable the quick identification and management of infectious diseases, respiratory conditions, and other health threats before they spread. The company has engaged in research and development collaborations with organizations such as DARPA and the NIH to validate its platforms and advance diagnostic capabilities for both medical and agricultural use cases.
delivered to your inbox.